Compare Nvidia Corp (NVDA) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nvidia Corp vs Summit Therapeutics Inc — how do they compare? Nvidia Corp trades at $229.59 (market cap $5.57T), while Summit Therapeutics Inc trades at $17.42 (market cap $13.71B). The key difference: Nvidia Corp is far larger — about 406.3× Summit Therapeutics Inc's market cap, and Nvidia Corp pays a 0.43% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nvidia Corp for 115 Days and Summit Therapeutics Inc for 16 Days on average.
| NVDA | SMMT | |
|---|---|---|
Market Cap | $5.57T | $13.71B |
Volume | 117,720,595 | 6,173,057 |
Sector | Technology | Health |
52-Week High | $239.27 | $26.38 |
52-Week Low | $165.17 | $12.43 |
Typical Hold Time | 115 Days | 16 Days |
Enterprise Value | $5.54T | $13.04B |
Dividend Yield | 0.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVIDIA (NVDA) trades at $229.25, down 3.42% over the past day amid a broader tech sell-off. The stock maintains a bullish technical signal with strong support near $228 and resistance at $235. Fundamentally, the company reported record revenue of $130.50B in 2025, with net income surging to $72.88B, reflecting a 55.84% profit margin. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.22 surpassing the $2.09 estimate. Analyst sentiment remains overwhelmingly positive, with a consensus price target of $339.17 implying significant upside.
NVDA's outlook is supported by robust AI chip demand and accelerating revenue growth, projected to reach $303.0B in 2026. However, risks include heightened competition, potential peak AI spending, and geopolitical tensions affecting market sentiment. The stock presents a compelling growth opportunity but requires monitoring of execution risks and macroeconomic headwinds.
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
